Autologous bone-marrow stem-cell transplantation for myocardial regeneration.

By C. Stamm, B. Westphal, H. Kleine, M. Petzsch, Prof. Dr. med. Gustav Steinhoff. The Lancet, 2003

1,426 citations recorded by the source corpus.

Implantation of bone-marrow stem cells in the heart might be a new method to restore tissue viability after myocardial infarction. We injected up to 1.5x10(6) autologous AC133+ bone-marrow cells into the infarct border zone in six patients who had had a myocardial infarction and undergone coronary artery bypass grafting. 3-9 months after surgery, all patients were alive and well, global left-ventricular function was enhanced in four patients, and infarct tissue perfusion had improved strikingly in five patients. We believe that implantation of AC133+ stem cells to the heart is safe and might induce angiogenesis, thus improving perfusion of the infarcted myocardium. See Commentary page 11

Subfields: Biomaterials, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/78f1a44fd2cf76c945331ae4e8c5574e4542abf1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Genetics

In Surgery

David Kaplan

Citations in the corpus

Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium (2004, background): “Our data are of particular importance given the fact that a variety of groups worldwide have initiated clinical trials of BM transplantation into ischaemic myocardiu”
From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells (2007, result): “All of the above-described results, along with similar studies (Assmus et al., 2002; Stamm et al., 2003), demonstrate that cell therapy with bone marrow-derived stem cells is feasible, safe, and may contribute to regeneration of myocardial tissue following infarction.”
Stem cell-based tissue engineering with silk biomaterials. (2006, background): “Bone marrow is the major source of MSCs and bone marrow-derived MSCs have been used to treat a variety of defects and diseases, including critical size segmental bone defects [134–136], full thickness cartilage defects [137–139], tendon defects [140], myocardial infarction [141] and even nerve defec”
Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral Sclerosis (2010, background): “Clinical trials have revealed the feasibility and safety of the clinical use of MSCs (for review, see Giordano et al(27)) and have provided some evidence of efficacy in various medical conditions.(28-34) On the basis of the preclinical experience and the cumulative data from clinical studies,(28-39)”
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration (2003, methodology): “5 × 10 6 autologous bone marrow–derived CD133 + cells were introduced into the infarct zone of six patients with AMI and coronary bypass graft”
Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. (2005, background): “Despite the recent negative reports about transdifferentiation (3, 16, 36), clinical trials with bone marrow-derived cell populations have been published and in part proven effective in the treatment of myocardial infarction (31, 33, 39).”